The University of Chicago Header Logo

Connection

Daniel Sulmasy to Informed Consent

Back to Details
This is a "connection" page, showing publications Daniel Sulmasy has written about Informed Consent.
Daniel Sulmasy
Connection Strength
2.732
Informed Consent
  1. Perceptions of control and unrealistic optimism in early-phase cancer trials. J Med Ethics. 2018 02; 44(2):121-127.
    View in: PubMed
    Score: 0.481
  2. Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials. J Empir Res Hum Res Ethics. 2017 10; 12(4):280-288.
    View in: PubMed
    Score: 0.479
  3. Patients' attitudes to informed consent for genomic research with donated samples. Cancer Invest. 2010 Aug; 28(7):726-34.
    View in: PubMed
    Score: 0.296
  4. Researchers' preferences and attitudes on ethical aspects of genomics research: a comparative study between the USA and Spain. J Med Ethics. 2009 Apr; 35(4):251-7.
    View in: PubMed
    Score: 0.270
  5. Informed consent without autonomy. Fordham Urban Law J. 2002 Nov; 30(1):207-20.
    View in: PubMed
    Score: 0.173
  6. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med. 1998 Oct; 105(4):266-74.
    View in: PubMed
    Score: 0.130
  7. The Impact of Unrealistic Optimism on Informed Consent in Early-Phase Oncology Trials. IRB. 2016 Sep-Oct; 38(5):1-7.
    View in: PubMed
    Score: 0.113
  8. Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer. 2016 Apr 15; 122(8):1238-46.
    View in: PubMed
    Score: 0.109
  9. Informed consent in emergency medicine: ethics under fire. Emerg Med Clin North Am. 1996 Feb; 14(1):245-54.
    View in: PubMed
    Score: 0.108
  10. Patients' perceptions of the quality of informed consent for common medical procedures. J Clin Ethics. 1994; 5(3):189-94.
    View in: PubMed
    Score: 0.094
  11. Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol. 2012 Dec 10; 30(35):4396-400.
    View in: PubMed
    Score: 0.086
  12. Unrealistic optimism in early-phase oncology trials. IRB. 2011 Jan-Feb; 33(1):1-8.
    View in: PubMed
    Score: 0.076
  13. The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010 Aug 01; 116(15):3702-11.
    View in: PubMed
    Score: 0.074
  14. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making. 2008 Jul-Aug; 28(4):575-81.
    View in: PubMed
    Score: 0.063
  15. Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer. 2005 Jan 01; 103(1):140-7.
    View in: PubMed
    Score: 0.050
  16. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth. 2003; 24(4):329-44.
    View in: PubMed
    Score: 0.044
  17. The call of the sirens: ethically navigating the sea of nonvalidated therapies. J Refract Surg. 1998 Sep-Oct; 14(5):559-66.
    View in: PubMed
    Score: 0.032
  18. Knowledge, confidence, and attitudes regarding medical ethics: how do faculty and housestaff compare? Acad Med. 1995 Nov; 70(11):1038-40.
    View in: PubMed
    Score: 0.027
  19. By whose authority? Emerging issues in medical ethics. Theol Stud. 1989 Mar; 50:95-119.
    View in: PubMed
    Score: 0.017
  20. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer. 2003 Jul 01; 98(1):166-75.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.